Table of Contents
ISRN Pulmonology
Volume 2013, Article ID 280843, 6 pages
http://dx.doi.org/10.1155/2013/280843
Clinical Study

Polymorphism of Beta2-Adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results

1Unità di Pneumologia, Università Cattolica S. Cuore, Largo A. Gemelli 8, 00168 Roma, Italy
2Department of Genetics, Catholic University, Largo A. Gemelli 8, 00168 Roma, Italy
3Department of Geriatrics, Campus Biomedico University, via Álvaro del Portillo 21, 00128 Roma, Italy

Received 20 February 2013; Accepted 11 March 2013

Academic Editors: Y. Dobashi and Y. Rojanasakul

Copyright © 2013 Leonello Fuso et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. B. Liggett, “Beta2-adrenergic receptor pharmacogenetics,” American Journal of Respiratory and Critical Care Medicine, vol. 161, pp. S197–S201, 2000. View at Google Scholar
  2. L. P. Chung, G. Waterer, and P. J. Thompson, “Pharmacogenetics of β2 adrenergic receptor gene polymorphisms, long-acting β-agonists and asthma,” Clinical and Experimental Allergy, vol. 41, no. 3, pp. 312–326, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Oostendorp, D. S. Postma, H. Volders et al., “Differential desensitisation of homozygous haplotypes of the beta2-adrenergic receptor in lymphocytes,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 3, pp. 322–328, 2005. View at Google Scholar
  4. F. D. Martinez, P. E. Graves, M. Baldini, S. Solomon, and R. Erickson, “Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing,” Journal of Clinical Investigation, vol. 100, no. 12, pp. 3184–3188, 1997. View at Google Scholar · View at Scopus
  5. J. J. Lima, D. B. Thomason, M. H. N. Mohamed, L. V. Eberle, T. H. Self, and J. A. Johnson, “Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics,” Clinical Pharmacology and Therapeutics, vol. 65, no. 5, pp. 519–525, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. D. R. Taylor, J. M. Drazen, G. P. Herbison, C. N. Yandava, R. J. Hancox, and G. I. Town, “Asthma exacerbations during long term β agonist use: influence of β2 adrenoceptor polymorphism,” Thorax, vol. 55, no. 9, pp. 762–767, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Israel, J. M. Drazen, S. B. Liggett et al., “The effect of polymorphisms of the beta2-adrenergic receptor on the response to regular use of albuterol in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 162, no. 1, pp. 75–80, 2000. View at Google Scholar
  8. E. Israel, V. M. Chinchilli, J. G. Ford et al., “Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial,” The Lancet, vol. 364, no. 9444, pp. 1505–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. M. E. Wechsler, E. Lehman, S. C. Lazarus et al., “Beta-adrenergic receptor polymorhysms and response to salmeterol,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 5, pp. 519–526, 2006. View at Google Scholar
  10. K. Basu, C. N. A. Palmer, R. Tavendale, B. J. Lipworth, and S. Mukhopadhyay, “Adrenergic β2-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol,” Journal of Allergy and Clinical Immunology, vol. 124, no. 6, pp. 1188–1194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. C. L. Carroll, P. Stoltz, C. M. Schramm, and A. R. Zucker, “β2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations,” Chest, vol. 135, no. 5, pp. 1186–1192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. R. J. Hancox, M. R. Sears, and D. R. Taylor, “Polymorphysm of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma,” European Respiratory Journal, vol. 11, no. 3, pp. 589–593, 1998. View at Google Scholar
  13. S. Tan, I. P. Hall, J. Dewar, E. Dow, and B. Lipworth, “Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics,” The Lancet, vol. 350, no. 9083, pp. 995–999, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Aziz, I. P. Hall, L. C. McFarlane, and B. J. Lipworth, “β2-Adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma,” Journal of Allergy and Clinical Immunology, vol. 101, no. 3, pp. 337–341, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. S. H. Kim, Y. M. Ye, G. Y. Hur et al., “Effect of β2-adrenergic receptor polymorphism in asthma control of patients receiving combination treatment,” Yonsei Medical Journal, vol. 50, no. 2, pp. 182–188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. E. R. Bleecker, D. S. Postma, R. M. Lawrance, D. A. Meyers, H. J. Ambrose, and M. Goldman, “Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies,” The Lancet, vol. 370, no. 9605, pp. 2118–2125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. C. Kips and R. A. Pauwels, “Long-acting inhaled β2-agonist therapy in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 6, pp. 923–932, 2001. View at Google Scholar · View at Scopus
  18. GINA, Global Initiative for Asthma, Global strategy for asthma management and prevention, 2008, http://ginasthma.org.
  19. American Thoracic Society, “Standardization of spirometry: 1994 update,” American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 3, pp. 1107–1136, 1995. View at Google Scholar
  20. G. Ryan, M. B. Dolovich, and R. S. Roberts, “Standardization of inhalation provocation tests: two techniques of aerosol generation and inhalation compared,” American Review of Respiratory Disease, vol. 123, no. 2, pp. 195–199, 1981. View at Google Scholar · View at Scopus
  21. M. E. Wechsler, S. J. Kunselman, V. M. Chinchilli et al., “Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial,” The Lancet, vol. 374, no. 9703, pp. 1754–1764, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. E. R. Bleecker, H. S. Nelson, M. Kraft et al., “β2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate,” American Journal of Respiratory and Critical Care Medicine, vol. 181, no. 7, pp. 676–687, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. E. R. Bleecker, S. W. Yancey, L. A. Baitinger et al., “Salmeterol response is not affected by β2-adrenergic receptor genotype in subjects with persistent asthma,” Journal of Allergy and Clinical Immunology, vol. 118, no. 4, pp. 809–816, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. B. J. Lipworth, O. J. Dempsey, and I. Aziz, “Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 β2-adrenoceptor polymorphism,” Chest, vol. 118, no. 2, pp. 321–328, 2000. View at Google Scholar · View at Scopus
  25. D. K. C. Lee, C. M. Jackson, C. E. Bates, and B. J. Lipworth, “Cross tolerance to salbutamol occurs independently of β2 adrenoceptor genotype-16 in asthmatic patients receiving regular formoterol or salmeterol,” Thorax, vol. 59, no. 8, pp. 662–667, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. E. R. Bleecker, D. A. Meyers, W. C. Bailey et al., “ADRB2 polymorphisms and budesonide/formoterol responses in COPD,” Chest, vol. 142, no. 2, pp. 320–328, 2012. View at Google Scholar
  27. A. Ullman and N. Svedmyr, “Salmeterol, a new long acting inhaled β2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients,” Thorax, vol. 43, no. 9, pp. 674–678, 1988. View at Google Scholar · View at Scopus
  28. M. Palmqvist, G. Persson, L. Lazer, J. Rosenborg, P. Larsson, and J. Lötvall, “Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency,” European Respiratory Journal, vol. 10, no. 11, pp. 2484–2489, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. M. G. H. Scott, C. Swan, T. M. Jobson, S. Rees, and I. P. Hall, “Effects of a range of β2 adrenoceptor agonists on changes in intracellular cyclic AMP and on cyclic AMP driven gene expression in cultured human airway smooth muscle cells,” British Journal of Pharmacology, vol. 128, no. 3, pp. 721–729, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. N. . Larocca, D. Moreno, J. V. Garmendia et al., “Beta 2 adrenergic receptor polymorphisms, at codons 16 and 27, and bronchodilator responses in adult Venezuelan asthmatic patients,” Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic, 2012. View at Publisher · View at Google Scholar
  31. M. Y. Lee, S. N. Cheng, S. J. Chen, H. L. Huang, C. C. Wang, and H. C. Fan, “Polymorphisms of the β2-adrenergic receptor correlated to nocturnal asthma and the response of terbutaline nebulizer,” Pediatrics and Neonatology, vol. 52, no. 1, pp. 18–23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. C. L. Carroll, K. A. Sala, A. R. Zucker, and C. M. Schramm, “Beta2-adrenergic receptor haplotype linked to intubation and mechanical ventilation in children with asthma,” Journal of Asthma, vol. 49, no. 6, pp. 563–568, 2012. View at Google Scholar
  33. S. B. Liggett, “Genetic variability of the β2 adrenergic receptor and asthma exacerbations,” Thorax, vol. 61, no. 11, pp. 925–927, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. G. A. Hawkins, K. Tantisira, D. A. Meyers et al., “Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study,” American Journal of Respiratory and Critical Care Medicine, vol. 174, no. 10, pp. 1101–1119, 2006. View at Google Scholar
  35. C. N. A. Palmer, B. J. Lipworth, S. Lee, T. Ismail, D. F. Macgregor, and S. Mukhopadhyay, “Arginine-16 β2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol,” Thorax, vol. 61, no. 11, pp. 940–944, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. I. P. Hall, J. D. Blakey, K. A. Al Balushi et al., “β2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study,” The Lancet, vol. 368, no. 9537, pp. 771–779, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. A. M. Wilson, R. D. Gray, I. P. Hall, and B. J. Lipworth, “The effect of β2-adrenoceptor haplotypes on bronchial hyper-responsiveness in patients with asthma,” Allergy, vol. 61, no. 2, pp. 254–259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. M. E. Wechsler and E. Israel, “How pharmacogenomics will play a role in the management of asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 1, pp. 12–18, 2005. View at Publisher · View at Google Scholar · View at Scopus